The most commonly reported side effects of ceftaroline include off label use, acute kidney injury, and neutropenia, based on 1,647 FDA adverse event reports from 2011 to 2025. 12.3% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for ceftaroline.
These are voluntary reports and do not establish that ceftaroline caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside ceftaroline. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
31.5% of ceftaroline adverse event reports involve female patients and 50.3% involve male patients. The largest age group is adult at 57%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking ceftaroline when the adverse event was reported.
Showing 15 of 259 indications
Ceftaroline is sold under the brand name Ceftaroline Fosamil.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.